Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by gudisgoodon Apr 11, 2021 5:45pm
117 Views
Post# 32975000

RE:RE:Evolution - 3rd phase

RE:RE:Evolution - 3rd phaseYou do know that a company cannot "reward" its shareholders with a higher stock price, right? The price of the stock is determined by the market. The only thing a company can do is to make intelligent decisions that increase shareholder value in the long run.

Eventually, the price of the stock will follow. "Eventually" may be months or years. That's not always fun when you own a bunch of shares. On the other hand, it sometimes gives you the opportunity to buy more stock at very attractive prices.

If you think a company like GBT is worthless in the hands of Goodman and the team, I have no idea why would have invested in GUD in the first place. Furthermore, now is not the time to complain about the company failing to make progress:

1) Knight has made a big entry into the LATAM market. This is a big deal for many reasons! The integration of GBT companies is still a year from being completed.
2) Knight has several products/markets in submitted, approved or early launch phases (see page 27 of the latest annual report).
3) Knight has Goodman and his team with almost $400M of cash, cash equivalents and marketable securities.  They will use this money for new launches, product and product portfolio acquisitions, in-licensing of drugs, branded generic drug development, bolt-on acquisitions, and strategic loans. They will make intelligent decisions with the money.

Exciting times! :)
<< Previous
Bullboard Posts
Next >>